Clipto

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clipto

Quick Facts

Property Description
Active ingredient Enalapril maleate
Form Oral Tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General purpose To lower vascular resistance and reduce cardiac workload
Origin Synthetic compound (Prodrug)

What Type of Medicine is Clipto?

Clipto is a prescription medication whose active ingredient is Enalapril maleate, a synthetic compound structurally belonging to the Angiotensin-Converting Enzyme (ACE) Inhibitor pharmacological class. This class works to modulate the body’s systemic mechanisms for regulating pressure.

Enalapril maleate is supplied for oral administration, typically as an oral tablet. It is characterized as a prodrug, which is a key distinction from some other medications. This means the compound administered is biologically inactive until it is chemically converted within the body to its potent therapeutic form, Enalaprilat, a feature clinically recognized for supporting a sustained duration of effect.


Enalapril: A Prodrug that Modulates the Body’s Pressure System

The core ingredient, Enalapril maleate, undergoes a vital biotransformation, primarily hydrolysis, after ingestion to become the active metabolite, Enalaprilat. This is the substance responsible for inhibiting the ACE enzyme.

By competitively hindering this enzyme, Enalaprilat blocks the synthesis of Angiotensin II, a powerful natural substance that causes blood vessels to constrict. This action effectively suppresses the Renin-Angiotensin-Aldosterone System (RAAS), a major signaling pathway governing pressure regulation. Pharmacological studies widely confirm that suppressing this vasoconstricting signal effectively modulates this systemic mechanism.


What is the General Therapeutic Purpose of Clipto?

The fundamental purpose of Clipto is to reduce overall vascular resistance within the circulatory system by promoting vasodilation (widening of the blood vessels).

This action, which alleviates constrictive signals in the vasculature, results in the general benefit of lowering elevated systemic pressure and consequently relieving the sustained workload on the heart. The overall reduction in resistance is consistently maintained to support smoother blood flow throughout the body.

What side effects are possible with Clipto?

Possible Side Effects and Safety Information

The safety profile of Clipto (Enalapril maleate) is established through regulatory classification of documented adverse reactions. These effects are systematically categorized by their frequency and the body system they affect in official labeling.


Frequency-Classified Adverse Reactions

Officially documented reactions range from Very Common (occurring in ge 1/10 patients) to Rare. Very Common effects include dizziness, headache, a persistent cough, and fatigue. Reactions classified as Common include orthostatic hypotension (a drop in pressure upon standing), which may lead to syncope, as well as nausea, diarrhea, and rash. The adverse effects are documented across key system-organ classes, such as Vascular disorders, Respiratory disorders, and the Nervous system.


Serious Safety Considerations

Official labeling identifies several serious adverse reactions. The most critical documented risk is angioedema, a rapid and severe swelling that can affect the face, tongue, or larynx, potentially obstructing the airway. Severe hypotension, an excessive reduction in systemic pressure, is also documented, which may infrequently lead to ischemic events like myocardial infarction in susceptible patients. Additionally, rare but serious effects involving the Blood and lymphatic system disorders, such as agranulocytosis, and complications like hepatic failure are listed in official documents.


Population and Time-Related Safety Patterns

Certain safety patterns are explicitly stated in regulatory texts. The risk of hypotension and syncope is highest at the initiation of therapy or following a dose escalation. For specific populations, use is highly restricted or contraindicated: the medication is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal toxicity. It is also constrained in patients with a history of angioedema related to ACE inhibitor use or those with bilateral renal artery stenosis. Use requires monitoring for the potential of elevated serum potassium levels (hyperkalemia).

Overdose and Emergency Response

Overdose and when to seek help

The primary clinical manifestation of an overdose of Clipto (Enalapril maleate) is profound hypotension, an excessive drop in blood pressure that can lead to syncope, dizziness, or loss of consciousness. This severe cardiovascular effect is documented in regulatory texts as a potential cause of secondary life-threatening outcomes, including Myocardial Infarction or Cerebrovascular Accident. The toxic profile also includes Hyperkalemia (high blood potassium) and the risk of Acute Renal Failure.

A critical, non-dose-dependent risk requiring urgent action is Angioedema (swelling of the face, throat, or tongue), with Laryngeal Edema posing a fatal risk of airway obstruction. Immediate medical attention must be sought for any sign of overdose or swelling; regulatory guidance stipulates calling emergency services or a Poison Help line.

Overdose management is symptomatic and supportive treatment, as no specific antidote is known. Procedures include placing the patient in the supine position and administering an Intravenous Infusion of Normal Saline to manage hypotension. Hospital monitoring of Blood Pressure, Electrolytes, and Creatinine is required for at least 6 to 24 hours depending on the patient's presentation. Patients with pre-existing volume depletion or severe heart failure face an increased risk of severe hypotension.

Therapeutic Uses of Clipto

What Clipto Treats: Main Uses and Benefits

Clipto (Enalapril) is a relevant medication often used in situations involving chronic cardiovascular conditions, focusing on easing symptoms related to systemic stress. It is relevant for use across conditions marked by increased physiological stress, including chronic hypertension (elevated blood pressure), symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction. It is commonly used to help with symptoms related to systemic imbalance.

In symptomatic congestive heart failure, it may assist with managing symptoms that create noticeable physiological strain, such as shortness of breath and physical fatigue. This offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is also relevant in specific clinical contexts, such as managing co-existing proteinuric chronic kidney disease alongside hypertension, where it may be part of symptomatic management in situations involving complex physiological stress.


Quick Fact: Relief for Sustained Systemic Stress

Feature Description
Primary Focus Used to help manage symptoms of high systemic pressure and poor cardiac output.
Key Symptoms Addressed Dyspnea, physical fatigue, and systemic pressure imbalance.
Core Patient Benefit Supports the patient’s long-term cardiovascular well-being and helps improve day-to-day comfort.
Contexts of Use Chronic management and preventative application in asymptomatic states.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Who Can Use Clipto

Clipto (Enalapril) is officially allowed for use in adults for all labeled indications. It is also approved for children starting at 1 month of age for the treatment of hypertension. Eligibility for use is defined by regulatory criteria that impose strict limits related to prior severe reactions, physiological conditions, and specific drug combinations.


Who Must Not Use Clipto (Contraindications)

The medicine is strictly contraindicated in patients with a history of angioedema (severe swelling) related to any prior ACE Inhibitor use, or if they have hereditary or idiopathic angioedema. Use is also prohibited during the second and third trimesters of pregnancy.

Furthermore, Clipto must not be taken concurrently with a neprilysin inhibitor (such as sacubitril/valsartan) or within 36 hours of switching to or from this drug class. Co-administration with aliskiren is contraindicated in patients with diabetes mellitus.


Populations Requiring Restrictions

Use is not recommended for neonates (infants le 1 month of age) or for pediatric patients with severe renal impairment (low glomerular filtration rate). For pregnancy, use is not recommended in the first trimester, and official guidance advises not to breastfeed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clipto (Enalapril maleate) has documented interaction patterns based strictly on government regulatory labeling. Co-administration with Sacubitril/Valsartan is formally contraindicated due to a significantly increased risk of angioedema. A strict 36-hour separation interval is mandated when transitioning between Clipto and Sacubitril/Valsartan. The use of Clipto is also contraindicated with Aliskiren in patients with diabetes mellitus or pre-existing renal impairment ( GFR < 60 ml/min/1.73 m^2).

The medicine’s official interaction profile includes substances affecting potassium balance. Co-administration with Potassium-Sparing Diuretics or Potassium Supplements may lead to hyperkalemia, a significant increase in serum potassium. Additionally, Clipto reduces the renal clearance of Lithium, potentially resulting in increased serum concentrations and toxicity.

Other documented interactions involve effects on blood pressure and renal function. Combining Clipto with other antihypertensive agents or certain vasodilators may result in additive hypotensive effects. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) risks the deterioration of renal function, an effect specifically noted in elderly or volume-depleted individuals. Furthermore, specific agents, including mTOR inhibitors and Racecadotril, are documented to increase the risk of angioedema. Regulatory information confirms that the absorption of Enalapril is not influenced by food.

Mechanism of Action

How Clipto Works: Mechanism of Action

Clipto operates through a two-step, bio-orthogonal activation mechanism to ensure highly selective drug action. First, a targeted carrier (such as an antibody conjugate) is administered, which binds specifically to antigens or receptors on the surface of the intended cells, serving as a delivery vehicle. The drug is chemically attached to this carrier in an inactive state (a prodrug).

Separately, a small-molecule activator is introduced, which initiates a non-enzymatic 'click' reaction (e.g., inverse electron-demand Diels–Alder) with the prodrug's linker. This chemical cleavage releases the active therapeutic agent only in the immediate vicinity of the target cells. This process restricts the active agent's exposure to non-targeted tissues, achieving a localized effect.

The released agent then acts as an inhibitor or disruptor of core intracellular pathways, such as those governing DNA replication or microtubule dynamics. Interference with these fundamental processes leads to programmed cell death ( apoptosis) in the affected target cell population, resulting in the physiological consequence of selective cellular disruption.

Dosage and Administration Information

How to Use Clipto

The administration of Clipto (Enalapril maleate) is structured around a precise initiation and titration protocol. The primary approved route of administration is oral, typically supplied as a tablet. The active metabolite, Enalaprilat, is also approved for intravenous use in select clinical settings. Clipto tablets may be taken with or without food as the drug's absorption is not clinically affected.

Official prescribing guidelines mandate that therapy must begin with a low, trial dose which is then gradually increased, a process known as titration. This adjustment period can extend over several weeks for certain conditions, such as heart failure, to establish the individualized maintenance amount. Dosing frequency usually follows a once-daily schedule for many hypertension patients, but a twice-daily schedule is required when initiating use for heart failure.

Indication Initial Oral Dose Maximum Daily Dose
Hypertension 5 mg once daily 40 mg
Heart Failure 2.5 mg twice daily 40 mg

Dosage is dependent on specific physiological factors. For instance, patients with reduced kidney function (creatinine clearance le 30 mL/min) must have their initial dose lowered to 2.5 mg once daily. Furthermore, the initiation of heart failure dosing requires close medical supervision to monitor the initial blood pressure response. If a scheduled dose is missed, it should be taken as soon as the lapse is noted, unless the time for the next dose is near, in which case the user should simply resume the regular schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clipto

Research regarding Clipto's role in chronic hypertension is based on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies compared measurements associated with Clipto against either placebo or other established therapies for high blood pressure. Researchers monitored measured reductions in systolic and diastolic blood pressure, and long-term studies monitored the rates of major cardiovascular events. Research also explored its use in subgroups like those with proteinuric chronic kidney disease, monitoring renal outcomes. Limited information is available regarding the long-term outcomes and sustained observation periods specifically for the pediatric population.


Evidence for Clipto in Symptomatic Heart Failure

The research regarding Clipto's role in symptomatic heart failure is derived from large-scale RCTs. The research primarily examined outcomes related to survival (all-cause and cardiovascular mortality) and the frequency of hospitalization events associated with heart failure. Studies also monitored objective physiological strain by assessing changes in measures of functional capacity. What remains uncertain are the findings on long-term outcomes for heart failure patients with advanced chronic kidney disease, as these patients were frequently excluded from the original pivotal trials.


Evidence for Clipto in Asymptomatic Dysfunction

Evidence for Clipto in patients who are asymptomatic (without outward symptoms) but have measurable heart function impairment comes from large-scale RCTs designed to monitor disease progression. Researchers focused on the measured progression rate to symptomatic heart failure and monitored event rates for mortality. Sub-studies used cardiac imaging to describe changes in the heart's dimensions. Results apply only to the populations studied, and research does not determine whether an individual who has not been similarly screened is expected to respond similarly.


Key Evidence Gaps

There is limited information on the long-term outcomes of studies involving Clipto across the entire spectrum of pediatric age groups. Comparative evidence against some of the newest classes of cardiovascular drugs is lacking in the historical trial data for Clipto itself.

Key Studies & References

  1. Studies of Left Ventricular Dysfunction (SOLVD) - Rationale, Design and Methods
  2. TEVA-ENALAPRIL Product Monograph (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Clipto (FAQ)

Q: What specific medical condition is Clipto prescribed for?

According to official product information, Clipto (Enalapril maleate) is primarily indicated for the treatment of hypertension (high blood pressure). It is also used for the treatment of symptomatic heart failure.


Q: What is the main active ingredient in Clipto?

The main active ingredient in Clipto is Enalapril maleate. The substance is converted in the body to its active metabolite, Enalaprilat, which is responsible for the drug's intended activity.


Q: What are the most commonly reported side effects of Clipto?

Studies and official information indicate that the most common adverse reactions include fatigue, dizziness and hypotension (low blood pressure). A dry, persistent cough is also frequently reported among patients taking this class of medication.


Q: Are there any rare or serious side effects associated with Clipto use?

Official warnings document serious but rare reactions. These can include angioedema (severe swelling of the face, tongue, or throat) and, in some cases, renal failure (kidney problems) or liver damage.


Q: Is it considered a normal experience for patients to feel tired when first starting Clipto?

The regulatory label lists fatigue as one of the most common adverse reactions observed in clinical trials. This is a recognized effect when initiating treatment with this medication.


Q: What are the signs of a non-severe allergic reaction to Clipto?

Official warnings primarily focus on the signs of serious allergic reactions (angioedema). These severe signs include swelling of the face, lips, tongue, or throat, and difficulty breathing.


Q: Does Clipto have any known interactions with specific blood pressure medications?

Yes, regulatory documents note that Clipto is contraindicated (should not be used) with Aliskiren in patients who have diabetes or kidney impairment. It also has documented interactions with certain diuretics and potassium-sparing agents.


Q: How quickly can a person expect to notice the effects or benefits of Clipto?

According to the official clinical information, the onset of the blood pressure-lowering effect is typically seen within 1 hour after taking an oral dose. The peak reduction in blood pressure usually occurs around 4 to 6 hours after administration.


Q: Is Clipto an appropriate treatment option for use in children?

Clipto is indicated for treating hypertension in children older than one month, as per specific regulatory guidance. However, it is not recommended for use in neonates (infants 1 month of age or less) or in pediatric patients who have severe kidney disease.


Q: Is Clipto safe to use during pregnancy, according to official classification?

Regulatory warnings state the medication should be discontinued as soon as pregnancy is detected. Drugs in this class are known to cause injury or death to the developing fetus, particularly when used during the second and third trimesters.


Q: Are there special requirements for how Clipto medication should be stored?

Special storage requirements depend on the form of the medication. The oral solution, for example, must be kept refrigerated or at room temperature for up to 60 days and must not be frozen. Tablets generally require storage at controlled room temperature.


Q: What does the available clinical research indicate about the long-term use of Clipto?

Clinical studies have shown that the antihypertensive effects of the medication can be maintained for at least 24 hours with recommended doses. However, regulatory warnings also document potential serious long-term risks may occur, such as renal failure and hyperkalemia (high potassium), which are points for discussion with a healthcare provider.


Q: Are there any specific vitamins or supplements that are known to interact with Clipto?

Official sources explicitly warn that the co-administration of potassium supplements or potassium salt substitutes with Clipto can increase the risk of developing significantly elevated potassium levels in the blood.


Q: Are there any specific foods, like grapefruit, that are known to interact with Clipto?

Official product labeling generally states that there are no known interactions between the active ingredient and common foods or drinks. This typically means specific foods like grapefruit do not need to be avoided.


Q: What health conditions or pre-existing diseases are listed as warnings for Clipto use?

Warnings are documented for patients with a history of angioedema, severe heart problems (like aortic stenosis), liver failure, or impaired renal function. These conditions may affect eligibility for treatment or require dose adjustment.


Q: Is it possible to crush or split the Clipto tablet if a person has trouble swallowing?

In cases where a patient has difficulty swallowing, some specialized instructions or authorized compounding guidance allow the tablets to be crushed and dispersed in water for simpler administration.


Q: Does Clipto affect a person's ability to operate heavy machinery or focus?

Official patient counseling information advises caution because the medication may affect coordination, reaction time, or judgment. Warnings caution against driving or operating machinery until an individual knows how the drug affects them.


Q: Is there specific eligibility information for older adults (seniors) using Clipto?

Regulatory guidance suggests that older adults may process the drug more slowly. Due to potential age-related kidney impairment, they may require a lower initial dose or closer medical supervision during treatment initiation.

How should Clipto be stored and disposed of?

Clipto (Enalapril maleate tablets) must be stored and disposed of strictly according to official regulatory guidelines.


Storage Requirements

The medication must be stored at Controlled Room Temperature, specifically 20 to 25 C (68 to 77 F) [Source 4.3]. Tablets must be protected from excess heat and moisture; therefore, they should not be stored in a place like a bathroom [Source 3.4]. Keep the tablets in the original container, which must be tightly closed [Source 3.4]. The medicine must be kept out of the sight and reach of children [Source 3.4].


Disposal Instructions

Disposal of unused or expired Clipto should be done through a drug take-back program whenever possible, as this is the preferred method [Source 1.4]. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance (like dirt or coffee grounds), sealed in a plastic bag, and then thrown into the household trash [Source 1.4]. Do not flush the medicine down the toilet or pour it down a drain, as it is not on the FDA's flush list [Source 1.4]. Disposal must comply with local/national waste regulations [Source 3.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clipto found in:

A-Z Index: